# US 2026/0209761 A1 · Rna-guided endonuclease system and use thereof in gene editing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0209761 A1
- Document ID: US20260209761A1
- Status: Published application
- Kind: A1
- Application number: 19/144,565
- Filed: 2024-01-02
- Published: 2026-07-23
- Earliest claimed: 2023-01-03
- Assignees: Harbin Institute of Technology; Westlake University
- Applicants: Harbin Institute of Technology; Westlake University
- Inventors: Zhiwei Huang; Fan Zhang; Kuan Ren; Fengxia Zhou
- Web page: https://patentgrep.com/patent/US20260209761A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 31/12: Antivirals
- C12N 7/045: {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 15/85: for animal cells
- C12N 15/86: Viral vectors
- C12N 15/90: Stable introduction of foreign DNA into chromosome
- C12Y 301/21: Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Provided in the present application are an RNA-guided endonuclease system and the use thereof in gene editing. The endonuclease complex includes an RNA-guided endonuclease and RNA, wherein the RNA-guided endonuclease includes an amino acid sequence selected from SEQ ID NOs: 1-57 and SEQ ID NOs: 150-191, guide RNA includes RNA associated with the RNA-guided endonuclease and targeting RNA, the RNA associated with the RNA-guided endonuclease includes the sequence of any one of SEQ ID NOs: 58-114 and SEQ ID NOs: 192-233, and the targeting RNA is at the 3′-end of the RNA associated with the RNA-guided endonuclease and is identical or complementary to the targeting sequence of a genome of interest. The endonuclease complex of the present application can be used for efficient gene cleavage and gene editing.

## Claims

### Claim 1

An endonuclease complex comprising an RNA-guided endonuclease and a guide RNA, wherein the RNA-guided endonuclease is IS607 TnpB protein and the guide RNA comprises RAGATH-18-associated RNA.

### Claim 2 (depends on 1)

The endonuclease complex of claim 1, wherein the RNA-guided endonuclease comprises a RuvC domain, and the RNA-guided endonuclease comprises an amino acid selected from the group consisting of Q8, G27, R30, N34, F50, W73, A92, F97, P104, K107, Y117, E145, P150, S173, G192, D194, G196, K198, A201, S204, N211, I212, N213, R227, Q229, 5233, R234, E237, G242, N249, K252, N266, V280, K283, P284, E290, L292, N293, G296, M297, M298, K299, L303, 5304, K305, Q310, K322, P338, S339, 5340, C343, C346, L353, L355, R358, C362, C364, D369, R370, D371, A374, N377 and L378 at an amino acid position corresponding to the amino acid sequence of SEQ ID NO: 6; optionally wherein the gene of interest is a single-stranded or double-stranded DNA, and optionally comprises a motif selected from the group consisting of NGGAG, NGGNN, AGGAG, GAGGG, GGGGG, NNGGG, NNAGG, AGGNN, NTAAA, NGAGG, NNGGN or GGGGN.

### Claim 3 (depends on 1)

Polynucleotides comprising a polynucleotide encoding the RNA-guided endonuclease in claim 1 and a polynucleotide encoding the RNA molecule in claim 1.

### Claim 4 (depends on 3)

A vector comprising the polynucleotides of claim 3, and optionally comprising an expression control sequence; wherein the RNA-guided endonuclease and the guide RNA are under the control of the same or different regulatory elements, optionally a promoter.

### Claim 5 (depends on 1)

A viral particle, optionally an adeno-associated viral particle, comprising the endonuclease complex of claim 1, polynucleotides comprising a polynucleotide encoding the RNA-guided endonuclease in claim 1 and a polynucleotide encoding the RNA molecule in claim 1 or a vector comprising the polynucleotides.

### Claim 6 (depends on 1)

A method for specifically cleaving DNA comprising contacting the endonuclease complex of claim 1 with the DNA,
optionally, the method comprises introducing polynucleotides comprising a polynucleotide encoding the RNA-guided endonuclease in claim 1 and a polynucleotide encoding the RNA molecule in claim 1, a vector comprising the polynucleotides or a viral particle into a cell, wherein the viral particle comprises the endonuclease complex of claim 1, the polynucleotides or the vector.

### Claim 7 (depends on 6)

The method of claim 6, wherein the method is performed in vivo or in vitro.

### Claim 8 (depends on 6)

The method of claim 6, wherein the method is performed under conditions selected from the group consisting of 0.5 to 10 mM of a divalent metal ion selected from the group consisting of Mg2+, Mn2+ and Ca2+, 25 to 250 mM Na+, a reaction temperature between 27 and 57° C. and a reaction time between 3 and 60 minutes.

### Claim 9 (depends on 1)

A method for gene editing comprising contacting the endonuclease complex of claim 1 with a genomic DNA of a cell for the gene editing.

### Claim 10 (depends on 1)

A kit comprising one or more of the following: the endonuclease complex of claim 1, polynucleotides comprising a polynucleotide encoding the RNA-guided endonuclease in claim 1 and a polynucleotide encoding the RNA molecule in claim 1, a vector comprising the polynucleotides, or a viral particle comprising the endonuclease complex, the polynucleotides or the vector.

### Claim 11 (depends on 1)

A method for inactivating or identifying a virus, comprising contacting the virus with the endonuclease complex or the endonuclease in claim 1, optionally wherein the endonuclease comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-57 and SEQ ID NOs: 150-191, or an amino acid sequence having at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one of SEQ ID NOs: 1-57 and SEQ ID NOs: 150-191.

### Claim 12 (depends on 1)

A method for treating infection with a virus, comprising administering the endonuclease complex of claim 1 to a patient infected with the virus.

### Claim 13 (depends on 3)

A viral vector comprising the polynucleotides of claim 3 or the vector comprising the polynucleotide molecule, optionally wherein the viral vector is an adeno-associated viral vector.

### Claim 14 (depends on 13)

A gene therapy method for treating a disease comprising using the viral vector of claim 13.

### Claim 15 (depends on 1)

A cell comprising one or more of the following: the endonuclease complex of claim 1, polynucleotides comprising a polynucleotide encoding the RNA-guided endonuclease in claim 1 and a polynucleotide encoding the RNA molecule in claim 1, a vector comprising the polynucleotides, or a viral particle comprising the endonuclease complex, the polynucleotides or the vector; optionally, the cell is a eukaryotic cell or a prokaryotic cell, optionally, the eukaryotic cell is a fungal cell, a plant cell or an animal cell.

### Claim 16 (depends on 1)

The endonuclease complex of claim 1, wherein the RNA-guided endonuclease comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 1-5, 7-57 and SEQ ID NOs: 150-191, or an amino acid sequence having at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to any one of SEQ ID NOs: 6, 1-5, 7-57 and SEQ ID NOs: 150-191;
the guide RNA comprises an RNA-guided endonuclease-associated RNA, and optionally further comprises a targeting RNA;
the RNA-guided endonuclease-associated RNA comprises the sequence of any one of SEQ ID NOs: 63, 58-62, 64-114, and SEQ ID NOs: 192-233 or a sequence having at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to the sequence of any one of SEQ ID NOs: 63, 58-62, 64-114, and SEQ ID NOs: 192-233;
the targeting RNA is at the 3′ end of the RNA-guided endonuclease-associated RNA and is at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical or complementary to a targeted sequence in a gene of interest, optionally the targeting RNA has a length of 12-40 bp;
optionally, the endonuclease system comprises an endonuclease of SEQ ID NO: N or a sequence having at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: N paired with an RNA guide sequence comprising SEQ ID NO: N+57 or a sequence having at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: N+57, wherein N is an integer of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, or 57; or the endonuclease system comprises an endonuclease of SEQ ID NO: M or a sequence having at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: M paired with an RNA guide sequence comprising SEQ ID NO: M+42 or a sequence having at least 30%, 40%, 50%, 60%, 70%, 80%, 85%, 95%, 96%, 97%, 98%, 99% or 100% identity to SEQ ID NO: M+42, wherein the M is an integer of 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, or 191.

### Claim 17 (depends on 1)

The endonuclease complex of claim 1, wherein the endonuclease complex comprises an RNA-guided endonuclease comprising SEQ ID NO: 6 and a guide RNA comprising SEQ ID NO: 63; an RNA-guided endonuclease comprising SEQ ID NO: 11 and a guide RNA comprising SEQ ID NO: 68; an RNA-guided endonuclease comprising SEQ ID NO: 13 and a guide RNA comprising SEQ ID NO: 70; an RNA-guided endonuclease comprising SEQ ID NO: 21 and a guide RNA comprising SEQ ID NO: 78; an RNA-guided endonuclease comprising SEQ ID NO: 43 and a guide RNA comprising SEQ ID NO: 100; an RNA-guided endonuclease comprising SEQ ID NO: 51 and a guide RNA comprising SEQ ID NO: 108; an RNA-guided endonuclease comprising SEQ ID NO: 52 and a guide RNA comprising SEQ ID NO: 109; an RNA-guided endonuclease comprising SEQ ID NO: 54 and a guide RNA comprising SEQ ID NO: 111; or an RNA-guided endonuclease comprising SEQ ID NO: 55 and a guide RNA comprising SEQ ID NO: 112.

### Claim 18 (depends on 6)

The method of claim 6, wherein the DNA is DNA of a eukaryotic cell, a prokaryotic cell or a virus;
and/or, the DNA is a single-stranded or double-stranded DNA;
and/or, the targeted sequence of the DNA comprises a motif selected from the group consisting of NGGAG, NGGNN, AGGAG, GAGGG, GGGGG, NNGGG, NNAGG, AGGNN, NTAAA, NGAGG, NNGGN or GGGGN, and the DNA at the 3′ end of the motif is at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical or complementary to the targeting RNA.

### Claim 19 (depends on 9)

The method of claim 9, wherein the gene editing results in an insertion and/or a deletion in the genomic DNA;
and/or, the gene editing is performed in a mammalian cell to treat or prevent a disease, or to introduce a desired trait.
